Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain

Next Previous
Search
Trial Profile

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of Olorinab in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olorinab (Primary)
  • Indications Abdominal pain
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CAPTIVATE
  • Sponsors Arena Pharmaceuticals

    • Most Recent Events

    • 01 May 2023 Results of subgroup analysis assessing efficacy and safety of olorinab to treat abdominal pain in patients with irritable bowel syndrome with diarrhea and constipation published in the Neurogastroenterology and Motility
    • 27 May 2021 Status changed from active, no longer recruiting to discontinued due to business decision.
    • 02 Mar 2021 According to an Arena Pharmaceuticals media release, full data from this trial will be shared an upcoming medical meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top